ODX in Blair article - Government Support?2 Oct 2020 10:50
Through its partnership with Mologic, the company is developing ELISA and lateral flow antigen tests that will use saliva as the sample type. These tests will offer a quicker time to result and an easier sample-collection method than current testing methods (particularly swab tests). The expectation is that the ELISA antigen test will be available by the end of September and the lateral flow test by the end of October or November. The lateral flow is the Heathrow test. I will urge caution here as my intention is not to ramp. This test is in prototype phase at the moment, and ODX are saying they are confident by end of the year, which contradicts Blair article.
But this is the interesting part....
Omega recently informed us that it is currently working towards manufacturing capacity for rapid tests of 0.5 million per week. The company believes it could double this quite quickly with government support – particularly in terms of financial and logistical support.
QUESTION for Monday : Are ODX seeking Government assistance to maximise manufacturing?
The demand for rapid testing
Look at the big boys below, and their numbers, to the best of my knowledge NONE of them are British. So for a British test, either AVCT or Mologic or any other LFT, to be made in Britain, they need BIG numbers quickly.
Roche, the multinational health-care company, announced in the beginning of September that it will produce around 40 million of its SARS-CoV-2 Rapid Tests per month. Its capacity is expected to increase more than twofold by the end of the year in order to help with the testing demand of health-care systems around the world.
By the end of September, BD, a leading global medical technology company, expects to increase the production of its rapid, point-of-care, SARS-CoV-2 diagnostic tests to 2 million tests per week.
Quidel is an American manufacturer of diagnostic health-care products that originally had the capacity to produce around 1 million of its rapid antigen tests per week. A recent grant from the National Institutes of Health has enabled Quidel to expand its production by about 140 million tests per year, according to company officials. The grant has allowed the company to support larger distribution centres, and its testing capacity has now reached around 220 million tests per year.
LumiraDX’s SARS-CoV-2 Ag Test is reported to be one of the fastest, most sensitive Covid-19 antigen point-of-care tests that is commercially available. The test uses a nose swab to detect antigens in around 12 minutes and the company is on track to produce 2 million tests in September and up to 10 million tests in December.
Abbott's BinaxNOW COVID-19 Ag Card is a rapid, portable, and affordable antigen test as it is the size of a credit card and will cost $5. Current estimates have Abbott shipping around 1 million tests per day, but Abbott plans on increasing the number of tests shipped to 10 million per month starting in October.
Sign In
Follow the stocks
